- 2026/07/06 Announcement of Important Resolution by allDirectors of the Company’s Important Subsidiary,MVA
- 2026/06/30 Publication of the U.S. Phase I Clinical Trialof OBP-301 for Esophageal Cancer
- 2026/06/29 Medigen Enrolls First Patient in PhaseI/II Clinical Trial of Allogeneic NK CellTherapy (Magicell-NK)
- 2026/06/08 Telomelysin (OBP-301) Officially Obtains Manufacturing and Marketing Approval in Japan
- 2026/06/03 Phase 1b/2a Clinical Trial Application Submitted to PMDA for a New OBP-301 Indication
- 2026/06/01 Announcement that the Company's Accumulated Disposal of Securities Has Reached the Public Announcement Standard
- 2026/05/26 Announcement of Important Resolutions from the 2026 Shareholders' Meeting of the Company
- 2026/05/22 Update on OBP-301: Conclusions from the Japanese MHLW Subcommittee Meeting
- 2026/05/14 The Progress Update of the New Drug under Development, OBP-301
- 2026/05/12 The Company's 2026 Q1 Consolidated Financial Statements Have been Approved by the Board of Directors